On-Demand WebinarEmerging new drug modalities are opening novel avenues to discover treatments for patients of previously unmet diseases. While promising, they also introduce complex and unpredictable side effects. Since traditional nonclinical safety testing poses limited translatability, the pharmaceutical industry is in need of new methodologies. Human 3D in vitro models enable more physiologically relevant models that may bridge this predictive gap. Through adjusting the complexity of cellular components and introducing immune components within the model, as well as modifying tissue architecture, these advanced models may ultimately improve drug safety assessment by providing insights into drug modality-mediated toxicities.Watch our on-demand webinar and hear our speakers Henriette Lanz, PhD (VP Biology at MIMETAS) and Dorota Kurek, PhD (Senior scientist at MIMETAS) discuss various topics.Webinar Highlights- Overview of diverse applications for assessing new drug modality-mediated toxicities, including peripheral neuropathy, vascular toxicity and intestinal toxicity, as well as immune-mediated hepatoxicity- Human relevance of organ-on-a-chip as an enabling technology to understand mechanisms underlying clinical adverse events to predict human safety risks of compounds- Future opportunities of microphysiological systems in toxicity testing